EAU 2013 - Programme Book - YouMed

ESU Courses
ESU Courses, 18 March
354 Programme Book
ESU Course 27
08.30 - 11.30 Diagnosis and management of non-muscle invasive bladder cancer
(NMIBC)
Green Hall 3 - Level N-1
Introduction and objective of course
J.A. Witjes, Nijmegen (NL)
Chair: J.A. Witjes, Nijmegen (NL)
Diagnosis of bladder cancer (including markers and importance of TUR) and case discussion
J. Palou, Barcelona (ES)
New diagnostic tools such as PDD and NBI
M. Babjuk, Prague (CZ)
Guideline treatment and follow-up including case discussion
J.A. Witjes, Nijmegen (NL)
Comments on guideline treatment recommendations including case example and discussion
M. Babjuk, Prague (CZ)
BCG failures and treatment options, including case discussion
J.A. Witjes, Nijmegen (NL)
What to do with extravesical urothelial cancer and case discussion
J. Palou, Barcelona (ES)
Closure and evaluation
Aims and objectives
With the comments of the last years this course will again fine tuned and obviously it will be updated
according to the 2013 EAU guideline and latest literature. The emphasis lies on the discussion of problems
seen in daily practice, when dealing with patients with non muscle-invasive bladder cancer (NMIBC). Many
of these problems have been raised in previous courses and are the basis for the current presentations and
case discussions. We have learned that discussion of these problems with the audience is very productive,
interactive and highly appreciated. So, although the emphasis is on what one should do (the EAU guideline
and its recommendations), we often see patients in daily practice that do not fit into guideline rules and need
a different approach. We will present potential options for these patients and discuss cases like that with the
audience to illustrate the possibilities beyond the guideline diagnosis and treatment solutions.
As can be seen in the program subjects that will be lectured, discussed and illustrated with cases are (1)
diagnostics (white light cystoscopy; cytology and markers; (re-)TUR technique), (2) diagnostic innovations
(PDD, NBI), (3) risk classification and therapy/follow per risk group, (4) potential exceptions to the guideline
recommendations (e.g. single post-TUR instillation, BCG maintenance therapy), (5) BCG failures, and finally
(6) urothelial carcinoma outside the bladder.